Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (48,235)	$ (20,672)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	2,168	1,639
Depreciation and amortization	22	47
Foreign Currency Transaction Gain (Loss), Unrealized	30,393	0
Accretion on marketable securities	893	1,925
Changes in operating assets and liabilities:
Prepaid and other current assets	29	(1,199)
Other assets	178	252
Accounts payable, accrued liabilities and other liabilities	(150)	367
Net cash used in operating activities	(14,702)	(17,641)
Cash flows from investing activities:
Purchase of marketable securities	(68,481)	(137,329)
Sale of marketable securities	93,865	66,035
Investment in Cend Therapeutics	(3,320)	0
Purchase of property and equipment	(259)	(60)
Net cash provided by (used in) investing activities	21,805	(71,354)
Cash flows from financing activities:
Proceeds from exercise of options	0	24
Tax withholding payments on net share settlement equity awards	(267)	(248)
Net proceeds from issuance of common stock	29	85,479
Net cash (used in) provided by financing activities	(238)	85,255
Effect of exchange rate changes on cash	(34)	0
Net increase (decrease) in cash and cash equivalents	6,831	(3,740)
Cash and cash equivalents at beginning of period	24,647	16,512
Cash and cash equivalents at end of period	31,478	12,772
Supplemental disclosure of noncash investing activities:
Issuance of common stock in connection with merger	23,580	0
Incremental fair value of Cend's fully vested stock options assumed	$ 2,136	$ 0